CLINICAL TRIALS PROFILE FOR LARTRUVO
✉ Email this page to a colleague
All Clinical Trials for LARTRUVO
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02584309 ↗ | Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | Active, not recruiting | Washington University School of Medicine | Phase 2 | 2016-02-22 | The purpose of this research study is to look at whether giving a drug called dexrazoxane with standard of care doxorubicin affects the progression of the disease. Dexrazoxane is often given at the same time as doxorubicin to help reduce the incidence and severity of disease of the heart muscle (which can be caused by doxorubicin). In January 2019 Eli Lilly and Company reported that the results of the Phase 3 study of olaratumab (Lartruvo), in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma, did not confirm the clinical benefit of olaratumab in combination with doxorubicin as compared to doxorubicin alone. Therefore olaratumab is being removed from the front line standard of care regimen. Amendment #9 was made to the protocol to reflect these changes to the standard of care treatment. |
| NCT03437070 ↗ | Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma | Withdrawn | Janssen Scientific Affairs, LLC | Phase 1 | 2019-06-01 | This study seeks to determine if addition of trabectedin (T) to combination doxorubicin (D) and olaratumab (O), is feasible and tolerable with antitumor activity in metastatic or recurrent Leiomyosarcomas (LMS) patients who have limited therapeutic options. |
| NCT03437070 ↗ | Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma | Withdrawn | University of Miami | Phase 1 | 2019-06-01 | This study seeks to determine if addition of trabectedin (T) to combination doxorubicin (D) and olaratumab (O), is feasible and tolerable with antitumor activity in metastatic or recurrent Leiomyosarcomas (LMS) patients who have limited therapeutic options. |
| NCT03719430 ↗ | APX005M and Doxorubicin in Advanced Sarcoma | Recruiting | Apexigen, Inc. | Phase 2 | 2019-03-20 | This phase II clinical trial will evaluate the safety and efficacy of adding APX005M (a CD40 agonistic monoclonal antibody) to doxorubicin for the treatment of patients with advanced soft tissue sarcoma. The investigators believe that doxorubicin, which is currently the standard of care for most advanced sarcomas, could work better when combined with APX005M, which is a type of immunotherapy. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LARTRUVO
Condition Name
Clinical Trial Locations for LARTRUVO
Trials by Country
Clinical Trial Progress for LARTRUVO
Clinical Trial Phase
Clinical Trial Sponsors for LARTRUVO
Sponsor Name
